Company: AZN
Filing Date: 2025-07-29
Form Type: 6-K
Source: 0001104659-25-071432
Chunk: 8

Company: ASTRAZENECA PLC
Filing Date: 2025-07-29
Form: 6-K
Chunk 8
---
 Phase III trial in uncontrolled or treatment resistant hypertension showed that two doses (2mg and 1mg) demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure compared with placebo at 12 weeks. The trial also successfully met all secondary endpoints. Patients received baxdrostat or placebo on top of standard-of-care. |

BioPharmaceuticals – R&I Breztri

| Phase III readout | KALOS/LOGOSMay 2025    | ●Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed thatBreztrimet all primary endpoints, demonstrating a statistically significant and clinically meaningful improvement in lung function compared with inhaled ICS/LABA medicines.                                                                                                                 |
| CHMP opinionEU    | NGP programmeJuly 2025 | ●Trixeo(Breztri), already licensed for the treatment of chronic obstructive pulmonary disease (COPD) in adults, has received a positive opinion from the CHMP endorsing it for use with an innovative, next-generation propellant with near-zero global warming potential. Based on the CHMP positive opinion, AstraZeneca will now begin to transition itsTrixeosupply to the next-generation propellant in Europe |

17

Fasenra

| Phase III readout​ | NATRONJune 2025New disclosure | ●Positive high-level results from the NATRON Phase III trial showed treatment withFasenra, dosed monthly in a single injection, demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of time to first worsening or flare versus placebo in patients with hypereosinophilic syndrome. The safety and tolerability profile forFasenrain this trial was consistent with the known profile of the medicine. The data will be presented at a forthcoming medical meeting and shared with regulatory authorities. |

Saphnelo

| Phase III readout​ | AZALEAJuly 2025New disclosure | ●Positive high-level results demonstrated thatSaphneloresulted in statistically significant and clinically meaningful improvement in the primary endpoint, BICLA Response at week 52, compared to placebo, in Asian patients with moderate to severe SLE despite standard-of-care. Improvements across secondary endpoints were also observed. The safety profile was generally consistent with the established safety profile. The data will be presented at a forthcoming medical meeting and shared with regulatory authorities. |

Airsupra

| Data presentationATS 2025 | BATURAMay 2025